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Purpose
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety
of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall
survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of
the study is to investigate predictive markers for trastuzumab-based chemotherapy.
Materials and Methods
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chem-
otherapy were analyzed retrospectively. 
Results
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85
years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%),
75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular ade-
nocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and
73 partial responses, the response rate was 50.6%. The median progression-free survival
(PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was
18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated
histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma)
on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly
inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6
months vs. 19.0 months, p=0.025). 
Conclusion
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy
may not be beneficial for Asians and patients with PDH, our data may suggest that even in
Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associ-
ated with improved clinical outcomes in patients with HER2-positive gastric cancer.
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Introduction
Gastric cancer is the fifth most common cancer worldwide,
with an estimated occurrence of almost one million new
cases every year, with half of the world total occurring in
East Asia [1]. In terms of mortality, it remains one of the most
common causes of cancer related mortality, only second to
lung cancer [2], as less than 50% of patients are eligible for
complete resection, and, in spite of recent progress, expected
survival duration with palliative treatment barely exceeds 1
year [3,4].
HER2 amplification or overexpression is known to occur
in approximately 15%-20% of patients with gastric cancer.
The pivotal Trastuzumab for Gastric Cancer (ToGA) trial [5]
demonstrated that patients with HER2-positive gastric or
gastroesophageal junction (GEJ) cancer may benefit from
trastuzumab, an anti-HER2 monoclonal antibody. In the
ToGA trial, patients assigned to receive trastuzumab in com-
bination with chemotherapy showed significant improve-
ment in overall survival (OS, 13.8 vs. 11.1 months), progr-
ession-free survival (PFS, 6.7 months vs. 5.5 months), and
overall response rate (ORR, 47% vs. 35%). In addition, an 
exploratory analysis demonstrated that patients with strong
protein expression (immunohistochemistry [IHC] 3[+] or
IHC 2[+]/fluorescence in situ hybridization [FISH] [+]) were
more likely to have favorable OS with the addition of
trastuzumab (16.0 months vs. 11.8 months). With these 
results, trastuzumab was approved as a standard treatment
option for HER2-positive gastric cancer patients. 
Meanwhile, the subset analysis of the ToGA trial generated
several questions. It is well-known that ethnicity matters in
gastric cancer [6]. Not only in terms of epidemiology, histol-
ogy, or pharmacodynamics, certain treatments which were
effective for a Western population did not show similar effi-
cacy in an Asian population, as in the AVAGAST trial [7]. In
fact, in the subset analysis of the ToGA trial, OS benefit was
not observed in the Asian population, while patients from
America and Europe did benefit from the treatment. In 
addition, according to the subset analysis of the ToGA trial,
patients with diffuse-type cancer who seldom harbor HER2
overexpression did not show OS benefit from trastuzumab-
based treatment. 
In the current study, we conducted a multicenter, retro-
spective analysis on HER2-positive gastric cancer patients
from 12 tertiary institutes in Korea, who were treated with
trastuzumab-based treatment in order to confirm whether
the clinical outcomes are affected by Asian ethnicity or his-
tology, and to provide further understanding of the disease
nature of HER2-positive gastric cancer.
Materials and Methods
1. Patients
Patients diagnosed with HER2-positive unresectable or
metastatic gastric cancer from 2009 to 2014 were included in
the analysis. The inclusion criteria were as follows: (1) a
pathologically confirmed diagnosis of gastric cancer; (2) HER2
positivity confirmed according to the criteria used in the
ToGA trial, that is, either IHC 3(+) or IHC 2(+)/FISH (+); (3)
treated with trasutuzumab-based chemotherapy as the first-
line treatment. Combined therapy could be continued after
six cycles according to physicians’ decision. (4) Complete
medical records, including demographics, site of primary
tumor, and pathologic reports. The study was approved by
the Institutional Review Board of the primary investigator’s 
institute, Samsung Medical Center.
2. Clinicopathologic parameters
Clinicopathologic parameters including age, sex, perform-
ance status, primary tumor site, Lauren’s classification,
World Health Organization (WHO) histologic classification,
measurability of lesions, methods for HER2 confirmation,
backbone chemotherapeutic regimen, and baseline labora-
tory findings were collected retrospectively from patients’
medical records.
3. Statistical analysis
OS was measured from the date of diagnosis of an unre-
sectable or metastatic disease to the date of death or last fol-
low-up, and PFS was measured from the date of diagnosis
of a metastatic or unresectable disease to the date of progres-
sive disease, death, or last follow-up. All survival parameters
were calculated using the Kaplan-Meier method and were
compared using a log-rank test. Tumor response was asse-
ssed using Response Evaluation Criteria in Solid Tumors ver.
1.0. p-values less than 0.05 were considered statistically sig-
nificant, and all p-values corresponded to two-sided signifi-
cance tests.
To assess whether higher HER2/CEP17 ratio affected PFS,
patients were dichotomized according to good survival
group (median PFS ! 6 months) versus poor survival group 
(median PFS < 6 months). The optimal cutoff for HER2/
CEP17 ratio for predicting a favorable PFS was determined
using receiver operating characteristic (ROC) curve analyses,
and further evaluation was performed using the area under
the curve (AUC). All statistical analyses were performed
using SPSS ver. 17 (SPSS Inc., Chicago, IL). 
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Results
1. Demographics and baseline disease characteristics
A total of 168 patients from 12 institutes were eligible for
the analysis. The median age of patients was 60 years (range,
27 to 85 years) and 118 patients (70.2%) were male. All 
patients were Asian. Regarding the location of the primary
tumor, 161 cases (95.8%) were stomach cancer and seven
cases (4.2%) were GEJ cancer. As many pathologists in Korea
do not interpret Lauren’s classification with biopsied speci-
mens, only 78 cases had been confirmed using Lauren’s clas-
sification, and among them, 44 (56.4%), 22 (28.2%), and 12
cases (15.4%) were found to be intestinal-type, diffuse-type,
and mixed-type cancer, respectively. However, WHO histo-
logic classification was confirmed in all cases, with 14 (8.3%),
63 (37.5%), 75 (44.6%), and 11 cases (6.5%) found to be well-
differentiated, moderately-differentiated, poorly-differenti-
ated tubular adenocarcinoma, and signet ring cell carcinoma,
respectively. In terms of methods for HER2 confirmation, in
129 patients disease was confirmed by IHC 3(+), and by IHC
2-3(+)/FISH (+) in 59 patients whose median value of
HER2/CEP17 ratio was 3.34 (range, 2.09 to 20.00). Other 
details are described in Table 1.
2. Clinical outcomes of trastuzumab-based therapy
Regarding the backbone regimen of the trastuzumab-
based therapy, 145 patients (86.3%) had received capecitab-
ine plus cisplatin, 14 patients (8.3%) had received 5- fluor-
ouracil (5-FU) plus cispaltin, and nine patients had received
other agents. Median number of cycles was six (range, 1 to
62) for both trastuzumab and chemotherapy. Tumor respo-
nses were as follows: 12 (7.1%) complete response, 73 (43.5%)
partial response, 48 (28.6%) stable disease, 17 (10.1%) pro-
gressive disease, and 18 (10.7%) cases were not evaluable, 
resulting in 50.6% of ORR (Table 2).
With a median follow-up duration of 32.9 months (95%
confidential interval [CI], 30.0 to 35.8), median PFS was 10.2
months (95% CI, 8.7 to 11.7), and median OS was 18.5 months
(95% CI, 16.4 to 50.6). Considering that Asian patients usually
achieve approximately 12 months of OS and 6 months of PFS,
the numerical data of the current study may suggest that
even in an Asian population, trastuzumab-based therapy
could be beneficial for patients with HER2-positive gastric
cancer.
Next, subset analysis was performed for survival accord-
ing to the histologic differentiation. Patients with well-dif-
ferentiated and moderately-differentiated tubular adenocarc-
inoma were categorized as the well-differentiated histologic
(WDH) group, and poorly-differentiated tubular adenocar-
Table 1. Demographics and baseline disease characteris-
tics 
Characteristic No. (%) (n=168)
Age, median (range, yr) 60 (27-85)
Sex
Male 118 (70.2)
Female 50 (29.8)
ECOG performance status
0 45 (26.8)
1 115 (68.5)
2 7 (4.2)
3 1 (0.6)
Primary tumor site
Gastroesophageal junction 7 (4.2)
Stomach 161 (95.8)
Previous gastrectomy
Not done 99 (58.9)
Subtotal gastrectomy 45 (26.8)
Total gastrectomy 24 (14.3)
Extent of disease
Locally advanced 54 (32.1)
Metastatic 114 (67.9)
Disease measurability
Measurable 97 (57.7)
Non-measurable 71 (42.3)
HER2 status
IHC 3(+)/FISH not done 109 (
IHC 2(+)/FISH (+) 39 (
IHC 3(+)/FISH (+)a) 20 (
WHO histologic classification
Well-differentiated tubular adenocarcinoma 14 (8.3)
Moderately-differentiated tubular 63 (37.5)
adenocarcinoma
Poorly-differentiated tubular adenocarcinoma 75 (44.6)
Signet ring cell carcinoma 11 (6.5)
Others 5 (3.0)
Lauren’s classification (n=78)
Intestinal 44 (56.4)
Diffuse 22 (28.2)
Mixed 12 (15.4)
Specimens confirmed as HER2 (+)b)
Surgical specimen 61 (
Endoscopic biopsied specimen 108 (
Specimens from metastatic site 12 (
ECOG, Eastern Cooperative Oncology Group; IHC, imm-
unohistochemistry; FISH, fluorescence in situ hybridiza-
tion; WHO, World Health Organization. a)Both IHC and
FISH were performed in these patients, b)Multiple speci-
mens could be sampled in a single patient.
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cinoma and signet ring cell carcinoma as poorly-differenti-
ated histologic (PDH) group. Consequently, 77 (45.8%) and
86 (51.2%) patients were classified as the WDH and PDH
group, respectively. The median PFS of the WDH group was
slightly longer than that of the PDH group, which did not
reach statistical significance (11.5 months [95% CI, 8.1 to 14.9]
vs. 8.9 months [95% CI, 7.2 to 10.6], p=0.16) (Fig. 1). However,
the median OS of two groups was significantly different; 19.0
months (95% CI, 14.2 to 23.8) for the WDH group; 14.6
months (95% CI, 11.9 to 17.3) (p=0.025) for the PDH group
(Fig. 2). Again, in numerical perspectives, these data of PDH
patients, that is, PFS of 8.9 months and OS of 14.6 months,
are better than the data from the typical Asian trial, which
might suggest that even patients of PDH could benefit from
trastuzumab-based therapy. Other than histologic differen-
tiation, Eastern Cooperative Oncology Group (ECOG) status
and serum albumin level were associated with survival
(Table 3).
ROC analysis was performed for 59 patients who were
confirmed as FISH (+) if a certain HER2/CEP17 ratio could
predict favorable PFS for trastuzumab-based treatment.
However, we could not determine optimal cutoff values for
favorable PFS (Fig. 3) and the AUC was calculated as lower
than 0.5. Higher ratios (3 or higher and 4 or higher) were not
associated with prolonged PFS (Table 4).
Table 2. Clinical outcomes of trastuzumab-based treat-
ment
Variable No. (%)
Backbone regimen
XP 145 (86.3)
FP 14 (8.3)
XELOX 6 (3.6)
Capecitabine 2 (1.2)
None (trastuzumab monotherapy) 1 (0.6)
Tumor response
Complete response 12 (7.1)
Partial response 73 (43.5)
Stable disease 48 (28.6)
Progressive disease 17 (10.1)
Missing 18 (10.7)
Overall survival, median (95% CI, mo) 18.5 (16.4-50.6)
Progression-free survival, 10.2 (8.8-11.6)
median (95% CI, mo)
XP, capecitabine plus cisplatin; FP, 5-fluorouracil (5-FU)
plus cisplatin; XELOX, capecitabine and oxaliplatin; CI,
confidence interval.
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Fig. 1.  Progression free survival according to the histo-
logic subtypes; 11.5 months (95% confidence interval [CI],
8.1 to 14.9) for patients with well-differentiated histology
(WDH), and 8.9 months (95% CI, 7.2 to 10.6) for patients
with poorly-differentiated histology (PDH).
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Fig. 2.  Overall survival according to the histologic sub-
types; 19.0 months (95% confidence interval [CI], 14.2 to
23.8) for patients with well-differentiated histology
(WDH), and 14.6 months (95% CI, 11.9 to 17.3) for patients
with poorly-differentiated histology (PDH).
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Discussion
Although several combinations have been introduced in
treatment of unresectable or metastatic gastric cancer pati-
ents, their prognosis remains poor. As a significant interest
in targeted therapies has emerged, a number of targeted
agents have been evaluated in gastric cancer. However, most
of them fell short of success [7-9], and trastuzumab is the
only agent with a known predictive biomarker and proven
efficacies. Clinical efficacy of ramucirumab and apatinib was
recently demonstrated in refractory gastric cancer patients;
however, their predictive biomarkers have not been found.
HER2 is a member of the epidermal growth factor receptor
family which promotes cell proliferation and inhibits apop-
tosis, and its overexpression has been described in various
human malignancies. Trastuzumab, a recombinant human-
ized anti-HER2 monoclonal antibody, was first developed as
a targeted agent for HER2-positive breast cancer, and its 
unprecedented successes heralded the era of target therapy
and relevant biomarkers in the field of oncology. As the car-
cinogenic roles of HER2 in gastric cancer had been sug-
gested, a randomized phase III trial commenced to assess the
clinical efficacy and safety of trastuzumab, which was fol-
lowed by a great success.
Ethnicity and regional variations should always be consid-
ered in management of gastric cancer. Not only the nation-
wide screening policies, epidemiology, pathogenesis,
anatomic location or dominant histology, treatment modali-
ties including surgical approaches and adjuvant treatment
also differ between Asian and Western countries [6]. In 
addition, several pharmacokinetic studies demonstrated that
efficacy and tolerability of fluoropyrimidine, a major anti-
neoplastic agent in management of gastric cancer, differ 
between Asian and Western people [10]. Owing to these fac-
tors, the clinical outcomes of Asian gastric cancer patients are
superior to those of Western patients. Therefore, mindfulness
of ethnicity is important in managing patients and in plan-
ning clinical trials as well. Given that HER2 overexpression
is frequently found in GEJ and intestinal-type cancer, HER2
overexpression rate might be lower in Asians, who tend to
have distal and diffuse-type cancers. However, several series
of surveys demonstrated that HER overexpression rate was
not low in Asians [11].
As prevalence of gastric cancer is high in Asia, many gas-
tric cancer trials have been conducted with Asians. In the
ToGA trial, among 584 patients, 319 (54.6%) were Asians,
and, as described above, Asians per se, were not associated
with OS benefit with trastuzumab-based treatment [5,12].
However, this could result from the fact that Asian gastric
cancer patients already have sufficient survival outcomes
with chemotherapy alone, probably due to subsequent treat-
ment which may attenuate the impact of effective combina-
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Fig. 3.  Receiver operating characteristics (ROC) curves for
identification of optimal cutoff values for favorable (6
months) progression-free survival. In this analysis, HER2/
CEP17 ratio was not associated with favorable progres-
sion-free survival. AUC, area under the curve.
Table 3. Survival durations according to other clinicolaboratory factors
Variable No. PFS, median (95% CI) p-value OS, median (95% CI) p-value
Albumin (g/dL)
" 3.0 19 7.3 (3.9-10.7) 0.012 14.3 (7.2-21.4) 0.064
! 3.1 148 9.4 (5.1-13.7) 18.7 (17.0-20.4)
ECOG PS
0 45 14.4 (7.8-21.0) 0.005 43.4 (7.7-79.1) < 0.001
1 or 2 122 9.2 (8.7-11.7) 15.7 (13.0-18.4)
PFS, progression-free survival; CI, confidence interval; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group
performance status.
tions as shown in the AVAGAST trial [7]. The benefit of
trastuzumab-based therapy in Asians might be suggested in
two recent Asian trials. In a Japanese study, 53 patients were
treated with trastuzumab combined with S-1 plus cisplatin,
and their median PFS and OS were estimated as 7.8 months
and 16.0 months [13]. And, in a Korean study, 55 patients
treated with trastuzumab combined with capecitabine and
oxaliplatin (XELOX) showed a median PFS of 9.8 months and
a median OS of 21.0 months [14]. Along with these data, our
retrospective analysis showed a median PFS and OS of 10.2
months and 18.5 months, respectively (Table 5). Considering
that Asians usually achieve PFS of 5 to 6 months and OS of
12 to 13 months with the first-line fluoropyrimidine and plat-
inum combinations [7,15], these numerical data imply that
Asians may also benefit from trastuzumab-based therapy in
the same manner with Western people. However, prospec-
tive head-to-head comparative analyses are warranted in
order to confirm the efficacy of trastuzumab-based therapy
in this unique population. 
Histologic subtype is one of the interesting issues in HER2-
positive gastric cancer. Gastric cancer can be categorized 
according to two distinct histologic subtypes, intestinal and
diffuse, which are distinct in their microscopic and gross 
appearance, epidemiology, pathogenesis, and prognosis [16].
Among them, diffuse-type gastric cancer is associated with
poor response to treatment and early relapse, thereby a
worse survival [17]. In the current study, we used WHO clas-
sification as a substitute for Lauren’s classification, as many
pathologists in Korea do not interpret Lauren’s classification
with endoscopic specimens due to fear of misreading, yet a
high concordance between two systems has been observed
[18]. Compared to the patients with WDH, the patients with
PDH showed worse clinical outcomes in both PFS (8.9
months vs. 11.5 months, p=0.16) and OS (14.6 months vs. 19.0
months, p=0.025). As these data are not head-to-head com-
parisons, it is difficult to make a firm conclusion whether 
patients with PDH can benefit from trastuzumab-based ther-
apy or not. Nonetheless, considering the numerical clinical
data usually reported in Asians, our data may imply that
even patients harboring PDH cancer could benefit from
trastuzumab-based therapy, although the degree is some-
what limited compared to patients with WDH.
In the perspective of frequency of HER2 overexpression or
amplification, it is more commonly found in intestinal-type
cancer than diffuse-type cancer. In the ToGA trial, 51 out of
584 patients (8.7%) had diffuse-type cancer, and in the
LOGiC trial, the differential became even more remarkable;
3.9% of patients (19/487) had diffuse-type cancer [19]. This
dominance of intestinal-type cancer in the two trials looks
suitable considering its disease nature. However, in our 
cohort, the number of patients with PDH (n=86, 51.2%) was
slightly higher than that of patients with WDH (n=77, 45.8%).
This could have resulted from the histologic distribution of
gastric cancer patients in Asia. Several large studies from
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Table 4. HER2/CEP17 ratio and progression-free survival
(n=59)
Ratio No. PFS, median (95% CI) p-value
0-2.99 22 10.2 (6.4-14.0) 0.64
! 3 37 9.8 (5.1-13.7) -
0-3.99 34 9.9 (6.8-13.0) 0.984
! 4 25 9.8 (5.7-13.9) -
PFS, progression-free survival; CI, confidence interval.
Table 5. Comparison of clinical outcomes of anti-HER2 trials for Asians
Trial Regimen ORR (%) PFS, median (95% CI, mo) OS, median (95% CI, mo) No.
HERBIS-1 [13] Trastuzumab (8!6 mg/kg) 68 7.8 (6.0-8.8) 16.0 (13.3-N/A) 53
SP
Ryu et al. [14] Trastuzumab (8!6 mg/kg) 68 9.8 (7.0-12.6) 21.0 (6.4-35.7) 55
XELOX
Present study Trastuzumab (8!6 mg/kg) 50.6 10.2 (8.7-11.7) 18.5 (16.4-50.6) 168
Various backbone regimens
ToGA trial [12]a) Trastuzumab (8!6 mg/kg) 64.4 6.2 (5-7) 15.9 (12-25) 51
XP or FP
LOGiC trial [19]b) Lapatinib 1,250 mg every day N/A N/A 16.5 (13.3-20.2) 100
XELOX
ORR, objective response rate; PFS, progression-free survival; CI, confidence interval; OS, overall survival; SP, S-1 plus cis-
platin; XELOX, capecitabine and oxaliplatin; XP, capecitabine plus cisplatin; FP, 5-fluorouracil plus cisplatin; N/A, not avail-
able. a)Japanese subset analysis, b)Asian subset analysis. 
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Asia demonstrated that diffuse-type or poorly-differentiated
cancer was more predominant [15,20]. Although these types
of gastric cancer do not harbor HER2 overexpression very
often, out-numbering of patients could draw the results. Sim-
ilar to our finding, in the TyTAN trial, which recruited
HER2-positive gastric cancer patients confined to Asia [21],
only 43% of patients had intestinal-type gastric cancer.
A HER2/CEP17 ratio was recently suggested as a novel
predictive marker for trastuzumab-based treatment. In a
Spanish trial, 66 FISH positive patients were evaluated and
HER2/CEP17 higher than 4.7 was identified as the cutoff
value for prolonged OS [22]. In another report by Ock et al.
[23], a HER2/CEP17 ratio of 4.48 clearly discriminated clin-
ical outcomes. In our study, however, we failed to find opti-
mal discriminating values for favorable PFS. This could have
resulted from the small number of samples, and our FISH
data did not come from a single laboratory. Tumor hetero-
geneity regarding the HER2 amplification could also be 
another factor [24]. Further analysis is requested on this
issue.
The current study has several limitations. Data were col-
lected in a retrospective manner and from multiple institutes.
This could draw somewhat inconsistent interpretation rega-
rding the favorable tumor response, such as complete or par-
tial responses. However, as we assessed PFS and OS, we
believe the validity of the conclusive data and rather, it may
reflect real world clinical outcomes. Although the backbone
regimens are varied, most of them (98.2%) are the combina-
tion of fluoropyrimidine (5-FU and capecitabine) and plat-
inum (cisplatin, oxaliplatin) which have similar efficacies and
can be used interchangeably. And, as we focused on the effi-
cacy of the treatment, the current analysis does not provide
ethnic or histologic difference of safety issue.
Conclusion
In conclusion, despite the result of subset analysis of the
ToGA trial, we might conclude that irrespective of ethnicity
or histologic subtypes, patients with HER2-positive gastric
cancer can benefit from trastuzumab-based chemotherapy.
Further analysis to find predictive biomarkers for these 
patients should be continued and ethnic difference and his-
tologic subtypes should be considered for future clinical tri-
als on gastric cancer patients.
Conflicts of Interest
Conflict of interest relevant to this article was not reported.
Author Details
1Division of Hematology-Oncology, Department of Internal
Medicine, Hanyang University Seoul Hospital, Seoul, 2Divi-
sion of Hematology-Oncology, Department of Internal Med-
icine, Gyeongsang National University School of Medicine,
Jinju, 3Division of Hematology/Oncology, Department of 
Internal Medicine, Chung-Ang University Hospital, Chung-
Ang University College of Medicine, Seoul, 4Division of
Hematology/Oncology, Department of Internal Medicine,
Gachon University Gil Hospital, Incheon, 5Department of 
Internal Medicine, Dankook University College of Medicine,
Cheonan, 6Division of Hematology and Oncology, Depart-
ment of Internal Medicine, Hanyang University Guri Hospi-
tal, Hanyang University College of Medicine, Guri, 7Division
of Hematology and Oncology, Department of Medicine,
Samsung Changwon Hospital, Sungkyunkwan University,
Changwon, 8Division of Oncology, Department of Medicine,
Yonsei University, Severance Hospital, Seoul, 9Department
of Internal Medicine, Dong-A University College of Medi-
cine, Busan, 10Department of Internal Medicine, Ewha Wom-
ans University School of Medicine, Seoul, 11Division of
Hematology-Oncology, Department of Internal Medicine,
VHS Medical Center, Seoul, 12Division of Hematology-
Oncology, Department of Internal Medicine, Kyung Hee
University School of Medicine, Seoul, 13Division of Hematol-
ogy-Oncology, Department of Medicine, Samsung Medical
Center, Sungkyunkwan University School of Medicine,
Seoul, Korea
Cancer Res Treat. 2016;48(2):553-560
560 CANCER  RESEARCH  AND  TREATMENT
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo
M, et al. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Can-
cer. 2015;136:E359-86.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
3. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Holler-
bach S, Hofheinz R, et al. Phase III trial in metastatic gastroe-
sophageal adenocarcinoma with fluorouracil, leucovorin plus
either oxaliplatin or cisplatin: a study of the Arbeitsgemein-
schaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-42.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Con-
stenla M, Boni C, et al. Phase III study of docetaxel and cis-
platin plus fluorouracil compared with cisplatin and
fluorouracil as first-line therapy for advanced gastric cancer:
a report of the V325 Study Group. J Clin Oncol. 2006;24:
4991-7.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,
Sawaki A, et al. Trastuzumab in combination with chemother-
apy versus chemotherapy alone for treatment of HER2-posi-
tive advanced gastric or gastro-oesophageal junction cancer
(ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 2010;376:687-97.
6. Macdonald JS. Gastric cancer: Nagoya is not New York. J Clin
Oncol. 2011;29:4348-50.
7. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park
SR, et al. Bevacizumab in combination with chemotherapy as
first-line therapy in advanced gastric cancer: a randomized,
double-blind, placebo-controlled phase III study. J Clin Oncol.
2011;29:3968-76.
8. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G,
et al. Capecitabine and cisplatin with or without cetuximab for
patients with previously untreated advanced gastric cancer
(EXPAND): a randomised, open-label phase 3 trial. Lancet
Oncol. 2013;14:490-9.
9. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et
al. Everolimus for previously treated advanced gastric cancer:
results of the randomized, double-blind, phase III GRANITE-
1 study. J Clin Oncol. 2013;31:3935-43.
10. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, et al.
Phase I pharmacokinetic study of S-1 plus cisplatin in patients
with advanced gastric carcinoma. J Clin Oncol. 2005;23:
6957-65.
11. Kim KM, Bilous M, Chu KM, Kim BS, Kim WH, Park YS, et al.
Human epidermal growth factor receptor 2 testing in gastric
cancer: recommendations of an Asia-Pacific task force. Asia
Pac J Clin Oncol. 2014;10:297-307.
12. Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku
N, et al. Efficacy of trastuzumab in Japanese patients with
HER2-positive advanced gastric or gastroesophageal junction
cancer: a subgroup analysis of the Trastuzumab for Gastric
Cancer (ToGA) study. Gastric Cancer. 2012;15:313-22.
13. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S,
Okuda H, et al. Phase II study of trastuzumab in combination
with S-1 plus cisplatin in HER2-positive gastric cancer (HER-
BIS-1). Br J Cancer. 2014;110:1163-8.
14. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, et al.
Multicenter phase II study of trastuzumab in combination
with capecitabine and oxaliplatin for advanced gastric cancer.
Eur J Cancer. 2015;51:482-8.
15. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Tak-
agi M, et al. S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): a phase
III trial. Lancet Oncol. 2008;9:215-21.
16. Lauren P. The two histological main types of gastric carci-
noma: diffuse and so-called intestinal-type carcinoma. An 
attempt at a histo-clinical classification. Acta Pathol Microbiol
Scand. 1965;64:31-49.
17. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC,
Ajani JA, et al. Updated analysis of SWOG-directed intergroup
study 0116: a phase III trial of adjuvant radiochemotherapy
versus observation after curative gastric cancer resection. J
Clin Oncol. 2012;30:2327-33.
18. Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, et al. Lau-
ren classification combined with HER2 status is a better prog-
nostic factor in Chinese gastric cancer patients. BMC Cancer.
2014;14:823.
19. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, et al. 
Lapatinib in combination with capecitabine plus oxaliplatin
(CapeOx) in HER2-positive advanced or metastatic gastric,
esophageal, or gastroesophageal adenocarcinoma (AC): The
TRIO-013/LOGiC Trial. J Clin Oncol. 2013;31 Suppl:Abstr
LBA4001.
20. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M,
Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer
with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:
1810-20.
21. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lap-
atinib plus paclitaxel versus paclitaxel alone in the second-line
treatment of HER2-amplified advanced gastric cancer in Asian
populations: TyTAN: a randomized, phase III study. J Clin
Oncol. 2014;32:2039-49.
22. Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fon-
seca P, et al. Level of HER2 gene amplification predicts 
response and overall survival in HER2-positive advanced gas-
tric cancer treated with trastuzumab. J Clin Oncol. 2013;31:
4445-52.
23. Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, et al. 
Optimal patient selection for trastuzumab treatment in HER2-
positive advanced gastric cancer. Clin Cancer Res. 2015;21:
2520-9.
24. Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, et al.
Clinical significance of intratumoral HER2 heterogeneity in
gastric cancer. Eur J Cancer. 2013;49:1448-57.
References
